ECSP099518A - Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico - Google Patents

Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico

Info

Publication number
ECSP099518A
ECSP099518A EC2009009518A ECSP099518A ECSP099518A EC SP099518 A ECSP099518 A EC SP099518A EC 2009009518 A EC2009009518 A EC 2009009518A EC SP099518 A ECSP099518 A EC SP099518A EC SP099518 A ECSP099518 A EC SP099518A
Authority
EC
Ecuador
Prior art keywords
metabolic syndrome
piranone
acid derivatives
treatment
derivatives replaced
Prior art date
Application number
EC2009009518A
Other languages
English (en)
Inventor
Hubert Heuer
Harm Brummerhop
Dieter Kadereit
Thomas Klabunde
Andreas Herling
Siegfried Stengelin
Matthias Urmann
Susanne Kilp
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39232744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099518(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP099518A publication Critical patent/ECSP099518A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)

Abstract

La invención se refiere al uso de derivados de ácido de piranona sustituidos y de sus sales fisiológicamente aceptables para producir medicamentos para tratar el síndrome metabólico.Se describe el uso de compuesto de la fórmula I, Ien la cual los radicales tienen los significados dados, así como sus sales fisiológicamente aceptables para producir un medicamento para tratar el síndrome metabólico.
EC2009009518A 2007-01-16 2009-07-15 Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico ECSP099518A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007002260A DE102007002260A1 (de) 2007-01-16 2007-01-16 Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms

Publications (1)

Publication Number Publication Date
ECSP099518A true ECSP099518A (es) 2009-08-28

Family

ID=39232744

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009518A ECSP099518A (es) 2007-01-16 2009-07-15 Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico

Country Status (31)

Country Link
US (1) US8748483B2 (es)
EP (1) EP2120923B1 (es)
JP (1) JP2010515765A (es)
KR (1) KR20090110834A (es)
CN (1) CN101600427A (es)
AR (1) AR064899A1 (es)
AU (1) AU2008207170A1 (es)
BR (1) BRPI0806661A2 (es)
CA (1) CA2675442A1 (es)
CL (1) CL2008000110A1 (es)
CR (1) CR10850A (es)
CY (1) CY1113148T1 (es)
DE (1) DE102007002260A1 (es)
DK (1) DK2120923T3 (es)
DO (1) DOP2009000177A (es)
EC (1) ECSP099518A (es)
ES (1) ES2390513T3 (es)
HR (1) HRP20120763T1 (es)
IL (1) IL199829A0 (es)
MA (1) MA31094B1 (es)
MX (1) MX2009006913A (es)
PE (1) PE20081700A1 (es)
PL (1) PL2120923T3 (es)
PT (1) PT2120923E (es)
RS (1) RS52494B (es)
RU (1) RU2009131058A (es)
SI (1) SI2120923T1 (es)
TN (1) TN2009000275A1 (es)
TW (1) TW200836716A (es)
UY (1) UY30871A1 (es)
WO (1) WO2008086949A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20150306002A1 (en) * 2012-12-13 2015-10-29 Merck Patent Gmbh 3-hydroxy-4-oxo-4h-pyran- or 3-hydroxy-4-oxo-1,4-dihydropyridine derivatives as protein-adhesive active substances
JP6338276B2 (ja) * 2014-07-10 2018-06-06 学校法人神奈川大学 抗癌剤
KR20240023691A (ko) * 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152148A (en) 1963-01-03 1964-10-06 Dow Chemical Co Preparation of comenic and pyromeconic acids
DE2966702D1 (en) 1978-06-26 1984-03-29 Measurex Corp Method and apparatus for measuring gas, including standardisation
JPS59125644A (ja) 1982-12-29 1984-07-20 Fujitsu Ltd 半導体装置
US4603144A (en) 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
GB8615041D0 (en) * 1986-06-20 1986-07-23 Silver J Pharmaceutical compositions
DE3728602A1 (de) 1987-08-27 1989-03-09 Bayer Ag Faserverstaerktes polyphenylensulfid
DE3728924A1 (de) 1987-08-29 1989-03-09 Bayer Ag Flammwidrige, thermoplastische formmassen auf basis von polycarbonat, polyalkylenterephthalat, pfropfcopolymerisat, fluoriertem polyolefin und phosphorverbindung
DE3729586A1 (de) 1987-09-04 1989-03-16 Ant Nachrichtentech Verfahren zum ausgleichen von durch den doppler-effekt hervorgerufenen laufzeit-verschiebungen der bursts in einem tdma-rahmen sowie anordnung
CA2007414C (en) 1989-04-26 1994-10-25 Clayton James Bennett Iii Method for manipulating elements within a structured document using active intent interpretations
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06271500A (ja) * 1993-03-23 1994-09-27 Noguchi Kenkyusho コマン酸の製造法
DE19530298C2 (de) * 1995-08-17 1999-07-22 Woerwag Pharma Gmbh Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1204654B1 (en) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: 5-ht2c serotonin receptor agonists
KR20020033778A (ko) 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
ATE369337T1 (de) 2000-04-28 2007-08-15 Asahi Kasei Pharma Corp Neue bizyklische verbindungen
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
DE10033353A1 (de) 2000-07-08 2002-01-24 Aventis Pharma Gmbh Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AU2002333456B2 (en) 2001-08-31 2008-07-17 Sanofi-Aventis Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as PPAR activators
US6552073B1 (en) 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10307004B3 (de) 2003-02-19 2004-08-05 Siemens Ag Verfahren zur Steuerung einer Brennkraftmaschine mit einer Lambda-Regelung

Also Published As

Publication number Publication date
US20100144862A1 (en) 2010-06-10
SI2120923T1 (sl) 2012-10-30
TN2009000275A1 (en) 2010-10-18
WO2008086949A1 (de) 2008-07-24
UY30871A1 (es) 2008-09-02
TW200836716A (en) 2008-09-16
DE102007002260A1 (de) 2008-07-31
MA31094B1 (fr) 2010-01-04
DK2120923T3 (da) 2012-10-29
RU2009131058A (ru) 2011-02-27
PE20081700A1 (es) 2009-01-08
RS52494B (sr) 2013-02-28
IL199829A0 (en) 2010-04-15
JP2010515765A (ja) 2010-05-13
AU2008207170A1 (en) 2008-07-24
DOP2009000177A (es) 2009-08-15
PT2120923E (pt) 2012-08-31
BRPI0806661A2 (pt) 2011-09-06
AR064899A1 (es) 2009-05-06
CN101600427A (zh) 2009-12-09
EP2120923A1 (de) 2009-11-25
US8748483B2 (en) 2014-06-10
ES2390513T3 (es) 2012-11-13
CL2008000110A1 (es) 2008-05-16
CY1113148T1 (el) 2016-04-13
HRP20120763T1 (hr) 2012-10-31
PL2120923T3 (pl) 2012-12-31
EP2120923B1 (de) 2012-07-18
CA2675442A1 (en) 2008-07-24
MX2009006913A (es) 2009-08-12
KR20090110834A (ko) 2009-10-22
CR10850A (es) 2009-10-16

Similar Documents

Publication Publication Date Title
ECSP099518A (es) Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
UY32848A (es) Compuestos heterocíclicos de oxima
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
CO6300957A2 (es) Derivados de imidazo -[1,2,b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
CO6781507A2 (es) Novedosos derivados heterociclicos
EA201200260A1 (ru) Гетероциклические гидразоны и их применение для лечения рака и воспаления
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo